ESC Guideline Recommendations for Monitoring Recovery from Acute Pericarditis

CRP Monitoring Strategy

The 2015 ESC Guidelines give a Class IIa recommendation that serum C‑reactive protein (CRP) should be measured to guide treatment length and assess therapeutic response in patients recovering from acute pericarditis. 1
During the first 1–2 weeks of therapy, CRP should be checked to evaluate the initial response to NSAIDs and colchicine. 1
CRP must be normal before any reduction in NSAID dose is initiated during the tapering phase. 1
Each step of NSAID tapering should only be performed when the patient is asymptomatic and CRP is within the normal range. 4
Periodic CRP assessment throughout the 3‑month colchicine course helps detect early recurrence of pericarditis. 1

Treatment length is guided by both symptom resolution and CRP normalization; for uncomplicated cases the typical duration is 1–2 weeks of full‑dose NSAIDs. 2
Full‑dose NSAIDs must be continued until both symptoms have resolved and CRP has normalized. 1
Aspirin taper: decrease the dose by 250–500 mg every 1–2 weeks. 2
Ibuprofen taper: decrease the dose by 200–400 mg every 1–2 weeks. 2
Premature tapering (within 1 month) raises the risk of recurrence; tapering should be gradual over several weeks rather than days. 2

Colchicine is prescribed for 3 months in a first episode of pericarditis, irrespective of CRP status. 2
Ongoing CRP monitoring during colchicine treatment aids early identification of recurrent inflammation. 1

Electrocardiogram (ECG) and echocardiography should be repeated until findings normalize, especially when clearance for physical exertion is required. 5
Non‑athlete patients should refrain from physical activity until symptoms, CRP, ECG, and echocardiogram are all normal. 1
Athletes require a minimum 3‑month restriction from sport until all above parameters have normalized. 1

While on NSAIDs, clinicians must monitor for gastrointestinal side effects and provide appropriate gastro‑protection. 2

Stopping therapy based solely on symptom resolution—without confirming CRP normalization—contributes to recurrence. 5
The recurrence rate after an initial pericarditis episode is 15–30 %, increasing to ≈ 50 % after a first recurrence when colchicine is not used. 5
Routine “scheduled” laboratory draws are discouraged; CRP should be obtained strategically at key decision points: before initiating taper, during taper if symptoms reappear, and when considering early discontinuation of therapy. 1